Bayer: Macular Degeneration trials

The registry lists 30 Macular Degeneration studies with Bayer as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 2 1Phase 3 4Phase 4 5No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular DegenerationCompletedNCT06591598Phase 4Results posted
• A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of TreatmentTerminatedNCT05473715Phase 4Results posted
• Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the EyeCompletedNCT04423718Phase 3Results posted
• Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the EyeCompletedNCT02581891Phase 4Results posted
• Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT02540954Phase 3Results posted
• Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular DegenerationCompletedNCT02305238Phase 4Results posted
• Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular DegenerationTerminatedNCT02222207Phase 2Results posted
• Aflibercept in Polypoidal Choroidal VasculopathyCompletedNCT02120950Phase 4Results posted
• VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)CompletedNCT01482910Phase 3Results posted
• Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)CompletedNCT00637377Phase 3Results posted
• A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular EdemaActive, not recruitingNCT06929143
• A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in EuropeCompletedNCT04067583
• Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular DiseaseCompletedNCT03939767
• Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.CompletedNCT03714308
• An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational StudiesCompletedNCT03521895
• A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin AmericaCompletedNCT03470103
• Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT03411941
• Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration PatientsCompletedNCT03382587
• Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical PracticeCompletedNCT03290794
• Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in GreeceCompletedNCT02821247
• Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for AfliberceptCompletedNCT02615496
• Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in CanadaCompletedNCT02585401
• Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in JapanCompletedNCT02541084
• Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular DegenerationCompletedNCT01933152
• Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular DegenerationCompletedNCT01914380
• Eylea Post Marketing Surveillance(PMS)CompletedNCT01783925
• Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF TherapyCompletedNCT01771081
• EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in JapanCompletedNCT01756261
• EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in JapanCompletedNCT01756248
• Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)CompletedNCT01447043